Sophia Genetics

The companies will combine their respective technologies to provide an integrated analytical and next-generation sequencing sample preparation offering for cancer research.

The co-marketing arrangement will initially cover hospitals and laboratories in Europe, the Middle East, and Africa.

Sophia's platform will be used to analyze data from Devyser's hereditary breast cancer and cystic fibrosis testing kits.

Internal benchmarks from the company show that the new technology, to be released next month, predicts variant pathogenicity with 98 percent accuracy.

The firms plan to combine Sophia's DDM software with Multiplicom's molecular diagnostic kits, and sell the solution to European hospitals and laboratories.

The partners will work on alternatives to current data protection methods which they say make healthcare data unusable for analysis, diagnostics.

The partnership will pair Sophia's informatics infrastructure with IDT's panel to provide an NGS-based solution for routine clinical diagnostics.

The companies are combining their respective products to provide a solution that covers genetic testing from sample prep to clinical reports.

The round was led by Belgian billionaire and founder of Omega Pharma Marc Coucke.

Genycell will distribute the Sophia Data Driven Medicine platform as part of a package to laboratories and hospitals in Spain and Portugal.

Pages

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.